FUB-APINACA (also known as A-FUBINACA according to the EMCCDA framework for naming synthetic cannabinoids and FUB-AKB48) is an indazole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug. It is an analog of APINACA and 5F-APINACA where the pentyl chain has been replaced with fluorobenzyl.
Pharmacology FUB-APINACA acts as a full agonist with a binding affinity of 1.06 nM at CB1 and 0.174 nM at CB2 cannabinoid receptors.
Legal status
In the United States, FUB-APINACA was temporarily emergency scheduled by the DEA in 2019. and made a permanent Schedule I Controlled Substance nationwide on April 7, 2022. Previously, it was illegal only in Alabama (listed as FUB-AKB48).Alabama Senate Bill SB 333: Controlled Substances
Sweden's public health agency suggested classifying FUB-APINACA as a hazardous substance on November 10, 2014.
See also
5F-ADB 5F-AMB AB-FUBINACA AB-CHFUPYCA AB-PINACA ADAMANTYL-THPINACA ADB-CHMINACA ADB-FUBINACA ADB-PINACA ADBICA APP-FUBINACA FAB-144 MDMB-CHMINACA MDMB-FUBINACA PX-3
References